Open access
Open access
Powered by Google Translator Translator

Oncology – Urological

Guideline | Management of metastatic castration-naive and castration-sensitive prostate cancer

23 Jan, 2023 | 13:33h | UTC

2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer – Canadian Urological Association Journal (PDF here)

See also: Summary of changes (PDF here)

Related: 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) – Canadian Urological Association Journal

 


CanRisk-Prostate | A comprehensive, externally validated risk model for the prediction of future prostate cancer

20 Jan, 2023 | 14:22h | UTC

CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer – Journal of Clinical Oncology

Commentary: Risk Model for Predicting the Development of Prostate Cancer – The ASCO Post

News Release: Prostate cancer risk prediction algorithm could help target testing at men at greatest risk – University of Cambridge

 


Consensus Statement | Management of patients with advanced prostate cancer

18 Jan, 2023 | 14:26h | UTC

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022 – European Urology

 


RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer

15 Jan, 2023 | 20:05h | UTC

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial – JAMA Oncology

News Release: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California

 

Commentary from the author on Twitter (thread – click for more)

 


Cohort Study | 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

11 Jan, 2023 | 14:10h | UTC

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


Review | Advances in diagnosis and treatment of testicular cancer.

16 Dec, 2022 | 13:25h | UTC

Advances in diagnosis and treatment of testicular cancer – The BMJ

 


Podcast | Prostate cancer: screening, advanced testing, and survivorship.

14 Dec, 2022 | 14:48h | UTC

#371 Prostate Cancer: Screening, Advanced Testing, and Survivorship – The Curbsiders

 


RCT | Rogaratinib vs. chemotherapy in patients with advancer urothelial carcinoma selected based on FGFR1/3 mRNA expression.

14 Dec, 2022 | 14:45h | UTC

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression – Journal of Clinical Oncology

Commentary: Rogaratinib Is Noninferior to Chemo in Pretreated FGFR1/3 mRNA+ Locally Advanced or Metastatic Urothelial Carcinoma – OncLive

 

Commentary on Twitter

 


RCT | Effects of prostate cancer screening with PSA and MRI followed by targeted biopsy only.

9 Dec, 2022 | 13:32h | UTC

Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: New prostate cancer diagnostic pathway paves way for general screening – University of Gothenburg

Commentary: MRI-Targeted Biopsy Beneficial for Men With Elevated PSA – HealthDay

 

Commentary on Twitter

 


RCT | Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer.

9 Dec, 2022 | 13:15h | UTC

DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Chemoresection Reduces Need for Surgery in Nonmuscle Invasive Bladder Cancer – Cancer Therapy Advisor

 

Commentary on Twitter

 


RCT | Olaparib with or without Cediranib for metastatic castration-resistant prostate cancer.

9 Dec, 2022 | 13:14h | UTC

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 – Journal of Clinical Oncology

Commentary: Olaparib Plus Cediranib for mCRPC Lowers Radiographic Progression Risk – Renal & Urology News

 

Commentary on Twitter

 


18F-sodium fluoride PET–CT vs. 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer.

22 Nov, 2022 | 13:09h | UTC

Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text) 

Commentary: 18F-NaF PET-CT More Accurate Than 99mTc-MDP SPECT for Detecting Bone Metastasis – Cancer Therapy Advisor 

 


PSMA and FDG-PET as predictive and prognostic biomarkers in patients given radioisotope therapy for prostate cancer.

22 Nov, 2022 | 12:56h | UTC

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text) 

Commentary: PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC – Targeted Oncology 

 


Guideline | Management of castration-resistant prostate cancer.

17 Nov, 2022 | 12:28h | UTC

2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) – Canadian Urological Association Journal

 


RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

11 Nov, 2022 | 13:55h | UTC

[News release – not published yet] Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – American Society for Radiation Oncology (ASTRO) Annual Meeting

 


RCT | Photodynamic vs. white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer.

31 Oct, 2022 | 13:51h | UTC

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT – Health Technology Assessment

 


[News Release] RCT | Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer.

27 Oct, 2022 | 12:32h | UTC

News Release: Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer – ASTRO Annual Meeting

Abstract: Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial – ASTRO Annual Meeting

 


RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.

27 Oct, 2022 | 12:23h | UTC

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: PRESIDE Trial Meets Primary End Point With Continuous Enzalutamide After Progression of mCRPC – Cancer Network

 


RCT | Effect of peritoneal fixation on lymphocele formation in robot-assisted radical prostatectomy with pelvic lymphadenectomy.

24 Oct, 2022 | 14:05h | UTC

Effect of Peritoneal Fixation (PerFix) on Lymphocele Formation in Robot-assisted Radical Prostatectomy with Pelvic Lymphadenectomy: Results of a Randomized Prospective Trial – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Consensus Recommendations | Radiation therapy in oligometastatic prostate cancer.

19 Oct, 2022 | 14:24h | UTC

Recommendations for Radiation Therapy in Oligometastatic Prostate Cancer: an ESTRO-ACROP Delphi consensus – Radiotherapy & Oncology

Related: AUA/ASTRO Guideline: Clinically localized prostate cancer.

 


Post-trial follow-up | Metastasis-directed therapy vs. observation in oligometastatic prostate cancer.

18 Oct, 2022 | 12:47h | UTC

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials – Journal of Clinical Oncology

Commentary: Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term – Cancer Therapy Advisor

 

Commentary on Twitter

 


Single-arm phase 2 study | A less intensive treatment strategy may be effective for patients with stage IIA and stage IIB seminoma.

17 Oct, 2022 | 12:25h | UTC

Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: De-escalation Strategy in Seminoma: An Alternative Option? – Medscape (free registration required)

 

Commentary on Twitter

 


M-A | Addition of androgen receptor targeted agents to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer.

27 Sep, 2022 | 13:02h | UTC

Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis – ESMO Open

 


Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.

21 Sep, 2022 | 13:10h | UTC

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer – Journal of Clinical Oncology

Commentary: High ORR Associated With Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Cancer – Cancer Network

 


RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.

19 Sep, 2022 | 12:31h | UTC

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary from the author on Twitter (thread – click for more)

 


Stay Updated in Your Specialty

No spam, just news.